Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 297.95 INR
Change Today -3.95 / -1.31%
Volume 745.8K
SVLS On Other Exchanges
Symbol
Exchange
Natl India
As of 7:34 AM 04/21/15 All times are local (Market data is delayed by at least 15 minutes).

suven life sciences ltd (SVLS) Snapshot

Open
302.60
Previous Close
301.90
Day High
305.00
Day Low
292.20
52 Week High
04/15/15 - 338.50
52 Week Low
04/21/14 - 74.18
Market Cap
37.9B
Average Volume 10 Days
2.0M
EPS TTM
0.72
Shares Outstanding
127.3M
EX-Date
07/24/14
P/E TM
412.0x
Dividend
0.50
Dividend Yield
0.84%
Current Stock Chart for SUVEN LIFE SCIENCES LTD (SVLS)

Related News

No related news articles were found.

suven life sciences ltd (SVLS) Related Businessweek News

No Related Businessweek News Found

suven life sciences ltd (SVLS) Details

Suven Life Sciences Limited, a research-based biopharmaceutical company, designs, manufactures, and supplies bulk actives, drug intermediates, and fine chemicals for the life science industry worldwide. It provides advanced intermediates, intermediates, and active pharmaceutical ingredients. The company also offers contract research and manufacturing services, including development and supply of pharmaceutical and agro chemical intermediates for new chemical entities. In addition, it provides discovery and development of new chemical entities for CNS disorders; research collaborative projects with pharmaceutical companies; and drug discovery research services, including in-vitro screening and molecular biology, drug metabolism and pharmacokinetics, pharmacology, toxicology and genotoxicity, and bioanalysis, as well as operates a formulation development center. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. Suven Life Sciences Limited was founded in 1989 and is based in Hyderabad, India.

Founded in 1989

suven life sciences ltd (SVLS) Top Compensated Officers

Executive Chairman, Chief Executive Officer, ...
Total Annual Compensation: 12.0M
Wholetime Director, Member of Share Transfers...
Total Annual Compensation: 5.4M
Compensation as of Fiscal Year 2014.

suven life sciences ltd (SVLS) Key Developments

Suven Initiates Multiple Ascending Dose Studies in Phase 1 Clinical Trial for Their Investigational Compound SUVN-G3031

Suven Life Sciences Ltd. announced that it has completed the single ascending dose studies of SUVN-G3031 in healthy human volunteers and initiated multiple ascending dose studies as a part of the Phase I study currently ongoing in USA under US-IND 123179. SUVN-G3031 is a potent, selective, brain penetrant and orally active Histamine H3 inverse agonist being developed for the treatment of cognitive dysfunction associated with Alzheimer's disease and Schizophrenia. The Phase-1 study was designed to evaluate the safety, tolerability and pharmacokinetics of SUVN-G3031 in healthy volunteers. The tolerability of SUVN-G3031 up to the higher dose administered in SAD study is excellent. No serious adverse events occurred. SUVN-G3031 demonstrated excellent pharmacokinetics with a potential for once in a day dosing. Histaminergic dysfunction has been strongly associated with the cognitive and behavioral deficits observed in several CNS disorders. Hence novel, potent, selective, brain penetrant and orally active H3 receptor inverse agonist for the treatment of cognitive deficits would offer new line of treatment for the unmet medical needs in Alzheimer's disease, Schizophrenia and other CNS disorders.

Suven Life Sciences Limited, Q3 2015 Earnings Call, Feb 13, 2015

Suven Life Sciences Limited, Q3 2015 Earnings Call, Feb 13, 2015

Suven Life Sciences Limited Appoints P. Subba Rao as Chief Financial Officer

Suven Life Sciences Limited announced that the Board of Directors of the company at its meeting held on February 10, 2015 has approved Mr. P. Subba Rao, the GM (Finance & Costing) as Chief Financial Officer (CFO) of the company.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SVLS:IN 297.95 INR -3.95

SVLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SVLS.
View Industry Companies
 

Industry Analysis

SVLS

Industry Average

Valuation SVLS Industry Range
Price/Earnings 30.4x
Price/Sales 7.0x
Price/Book 11.7x
Price/Cash Flow 30.5x
TEV/Sales 7.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUVEN LIFE SCIENCES LTD, please visit www.suven.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.